In this week’s episode of The Spotlight Roundup, we spotlight Field Trip Health as they complete the largest financing raise ever for a psychedelic company in Canada; Red Light Holland completes the sale and import of psychedelic truffles into Canada; Mind Cure Health launches a product sales division; and we look at New York, which may be on the brink of a big psychedelic boom.
In this episode of the Psychedelic Spotlight podcast, we feature…
This week in psychedelic business news: An all-female biotech company, psychedelic-assisted psychotherapy for COVID front-liners, and more.
In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.
In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?
The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?
Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.
Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.
It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.
James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.
In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Cybin #Psilocybin #Psychedelics
![Important UPDATE : MindMed’s 2020 Year-End Financial Results [ Good News for MMED / MMEDF! ]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-91-600x338.jpeg)
Hey Psychedelic Investors! For those of you following MindMed, today’s episode is based on MindMed’s press release where MMED announced their 2020 year-end Financial results.
What was covered in MindMed’s press release?
1. MMED ‘ s total assets
2. MindMed’s Net Cash Operating Activities
3.MMEDF ‘s Net loss
4. The company’s Cash on Hand
5. The date and hour for MindMed ‘s earnings call
MMED / MMEDF / MMQ ‘ stock has been experiencing a little fall lately… As long as the price doesn’t fall below $2 USD, we should still be good-ish in terms of the NASDAQ stock price requirements.. Hopefully it won’t fall below that threshold!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
In the realm where music meets the mystical, few artists embody the fusion of psychedelic exploration and sonic innovation like Mendeleyev.
In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
